Catalpol regulates cholinergic nerve system function through effect on choline acetyl-transferase not M receptor affinity

Wang, Jinhong; Xie, Hai; Zhao, Tingkun; Kang, Bai

doi:10.1016/j.biopha.2014.12.014

Cited by 8 publications

(7 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Catalpol modulates cholinergic nervous system function through its effect on ChAT. Catalpol may be helpful in the treatment of AD but has no effect on M receptor affinity [ 64 ]. The activity of acetylcholinesterase (AChE) in the brain of aging mice was increased, the activity of ChAT positive neurons in the basal forebrain of aging mice was significantly decreased, and the expression of muscarinic acetylcholine receptor M1 (MAChR1) was decreased.…”

Section: Potential Mechanism Of Catalpol In the Treatment Of Admentioning

confidence: 99%

Effects of Catalpol on Alzheimer’s Disease and Its Mechanisms

Chen

Deng

Meng

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is a degenerative disease of the central nervous system characterized by memory loss and cognitive dysfunction. With the increasing aging of the population, the incidence of AD and the number of patients are also increasing year by year, causing more and more heavy burdens to the family and society. Catalpol, an iridoid glycoside compound, is one of the main active components of Rehmannia glutinosa. At present, a large number of experimental studies in vivo and in vitro have confirmed that catalpol has antioxidant, anti-inflammatory, antiapoptotic, and other neuroprotective effects, and it plays a significant role in the prevention and treatment of AD, with very small side effects and high safety. Therefore, it may be an ideal drug for the treatment of AD. Based on this, the role and mechanism of catalpol in AD will be comprehensively reviewed in the following.

show abstract

Section: Potential Mechanism Of Catalpol In the Treatment Of Admentioning

confidence: 99%

Effects of Catalpol on Alzheimer’s Disease and Its Mechanisms

Chen

Deng

Meng

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…Also, epidemiological data indicate that patients with DM are at higher risk of developing dementia or Alzheimer’s disease (AD) than the non-diabetic population [92]. Considering the substantial evidence that multiple genes and proteins (amyloid β-protein (Aβ)40, Aβ42 [93], choline acetyl-transferase [94], protein kinase C [95], adrenocorticotropic hormone, corticotropin releasing hormone [96]) expressions could be modulated by catalpol in protection against AD, these may also become new potential targets in the management of DE.…”

Section: Pharmacological Actions Of Catalpol In the Management Of mentioning

confidence: 99%

Catalpol in Diabetes and its Complications: A Review of Pharmacology, Pharmacokinetics, and Safety

et al. 2019

View full text Add to dashboard Cite

This review aimed to provide a general view of catalpol in protection against diabetes and diabetic complications, as well as its pharmacokinetics and safety concerns. The following databases were consulted with the retrieval of more than 100 publications through June 2019: PubMed, Chinese National Knowledge Infrastructure, WanFang Data, and web of science. Catalpol exerts an anti-diabetic effect in different animal models with an oral dosage ranging from 2.5 to 200 mg/kg in rats and 10 to 200 mg/kg in mice. Besides, catalpol may prevent the development of diabetic complications in kidney, heart, central nervous system, and bone. The underlying mechanism may be associated with an inhibition of inflammation, oxidative stress, and apoptosis through modulation of various cellular signaling, such as AMPK/PI3K/Akt, PPAR/ACC, JNK/NF-κB, and AGE/RAGE/NOX4 signaling pathways, as well as PKCγ and Cav-1 expression. The pharmacokinetic profile reveals that catalpol could pass the blood-brain barrier and has a potential to be orally administrated. Taken together, catalpol is a well-tolerated natural compound with promising pharmacological actions in protection against diabetes and diabetic complications via multi-targets, offering a novel scaffold for the development of anti-diabetic drug candidate. Further prospective and well-designed clinical trials will shed light on the potential of clinical usage of catalpol.

show abstract

“…The vast arrays of neuroprotective effects of iridoids and some monoterpenes are shown in Table 1 [ 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 ]. The Aβ formation, aggregation and function have been the major target areas of AD for in vitro experiments.…”

Section: Therapeutic Potential For Alzheimer’s Diseasementioning

confidence: 99%

“…In other experiments, Aβ was directly injected into the brain to study the biochemical and behavioral changes in animals. Catalpol was among the iridoids showing activity in this model where prevention of the ACh neuronal damage was noted from the increased level of choline CHAT positive cells density in cerebral cortex as well as increased level of ChAT activity [ 28 ]. Geniposide also ameliorated the Aβ-induced neuronal abnormalities including cellular densities and synaptic proteins level in the transgenic mice model [ 63 ].…”

Section: Therapeutic Potential For Alzheimer’s Diseasementioning

confidence: 99%

Iridoids and Other Monoterpenes in the Alzheimer’s Brain: Recent Development and Future Prospects

Habtemariam

2018

Molecules

View full text Add to dashboard Cite

Iridoids are a class of monoterpenoid compounds constructed from 10-carbon skeleton of isoprene building units. These compounds in their aglycones and glycosylated forms exist in nature to contribute to mechanisms related to plant defenses and diverse plant-animal interactions. Recent studies have also shown that iridoids and other structurally related monoterpenes display a vast array of pharmacological effects that make them potential modulators of the Alzheimer’s disease (AD). This review critically evaluates the therapeutic potential of these natural products by assessing key in vitro and in vivo data published in the scientific literature. Mechanistic approach of scrutiny addressing their effects in the Alzheimer’s brain including the τ-protein phosphorylation signaling, amyloid beta (Aβ) formation, aggregation, toxicity and clearance along with various effects from antioxidant to antiinflammatory mechanisms are discussed. The drug likeness of these compounds and future prospects to consider in their development as potential leads are addressed.

show abstract

Catalpol regulates cholinergic nerve system function through effect on choline acetyl-transferase not M receptor affinity

Cited by 8 publications

References 28 publications

Effects of Catalpol on Alzheimer’s Disease and Its Mechanisms

Effects of Catalpol on Alzheimer’s Disease and Its Mechanisms

Catalpol in Diabetes and its Complications: A Review of Pharmacology, Pharmacokinetics, and Safety

Iridoids and Other Monoterpenes in the Alzheimer’s Brain: Recent Development and Future Prospects

Contact Info

Product

Resources

About